Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
KESTRA Medical Technologies, Ltd. officer Raymond Cohen reported a proposed sale of 3,330 common shares, with an aggregate market value of $97,503.90, through Merrill Lynch. The approximate sale date is September 30, 2026, on Nasdaq. The shares are identified as coming from restricted stock unit awards that vested September 4, 2026, under the issuer’s equity compensation plan.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director Elizabeth Kwo sold 4,010 common shares on September 21, 2026, at a weighted average price of $24.2563 per share. The sale was described as a nondiscretionary sell-to-cover transaction to satisfy tax withholding obligations tied to restricted stock unit vesting and settlement. Her direct holdings after the sale were 14,116 common shares.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a notice of proposed sale under Rule 144 filed for the account of officer Elizabeth Kwo. The notice covers up to 4,010 shares of common stock, to be sold through Merrill Lynch, with a proposed sale date of September 21, 2026.
The shares relate to common stock acquired on September 4, 2026 upon the vesting of restricted stock unit awards granted as part of the issuer’s equity compensation plan.
Kestra Medical Technologies (KMTS) reported strong top-line growth for the quarter ended July 31, 2026, with revenue of $31.0 million, up 60% from $19.4 million a year earlier, driven by more patients using its ASSURE wearable cardioverter defibrillator system. Gross profit nearly doubled to $17.5 million as cost per patient declined due to better equipment utilization and manufacturing efficiencies. Operating expenses rose sharply, with research and development at $6.8 million and selling, general and administrative at $48.4 million, contributing to a wider net loss of $44.1 million versus $25.8 million. Kestra ended the quarter with $244.7 million in cash, cash equivalents and investments and $72.5 million of long-term debt after drawing a new $75 million term loan and extinguishing its prior facility, which generated a $6.3 million loss on debt extinguishment. Management states that existing liquidity is expected to fund operations and capital needs for at least the next 12 months, while acknowledging potential future funding needs if growth investments or cash burn exceed expectations.
Kestra Medical Technologies, Ltd. (KMTS) reported first quarter fiscal 2027 results for the period ended July 31, 2026, highlighted by rapid top-line growth but widening losses. Revenue reached $31.0 million, a 60% increase from $19.4 million a year earlier, driven by wearable cardioverter defibrillator market expansion, competitive share gains, new territories, a higher mix of in-network patients, and better revenue cycle management.
Gross profit rose to $17.5 million, with gross margin expanding to 56.5% from 45.7% on volume leverage, more in-network patients, and cost improvements. GAAP operating expenses increased to $55.2 million from $37.7 million, and GAAP net loss widened to $44.1 million from $25.8 million. Adjusted EBITDA loss was $24.0 million, compared with a $19.4 million loss. Kestra ended the quarter with $244.7 million in cash, cash equivalents and investments and reported total liquidity of approximately $320 million, including committed unused term loan availability. The company raised FY27 revenue guidance to $141 million, implying 48% growth versus FY26 and up from prior guidance of $137 million.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director and ten percent owner Jeffrey Lawrence Schwartz reported both an equity award and a tax-related sale of common shares. On September 9, 2026, he acquired 7,217 restricted stock units (RSUs), each convertible into one common share, which vest on September 9, 2027 subject to continued service.
On September 8, 2026, he sold 3,890 common shares at a weighted average price of $25.178 per share, with prices ranging from $24.91 to $25.424, in a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations tied to RSU vesting and settlement. He is also reported as having indirect ownership of 25,172,338 common shares held by Bain Charger Holdings, L.P., where he may be deemed to share voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
KESTRA MEDICAL TECHNOLOGIES, LTD. (symbol: KMTS) is the issuer of record for a Form 4 filing submitted to the SEC. Kwo Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported that director Elizabeth Kwo received a grant of 7,217 restricted stock units, each representing one common share. After this award, she has 18,126 common shares reported as directly held. The restricted stock units vest on September 9, 2027, subject to her continued service through that date. No Rule 10b5-1 trading plan is reported for this transaction.
KESTRA MEDICAL TECHNOLOGIES, LTD. (symbol: KMTS) is the issuer of record for a Form 4 filing submitted to the SEC.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director Hanley Conor reported two equity transactions: a grant of 7,217 restricted stock units, each convertible into one common share and vesting on September 9, 2027 subject to continued service, and a sale of 5,694 common shares on September 8, 2026 at a weighted average price of $25.2509 per share. The sale was a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director Kevin C. Reilly reported two equity-related transactions. On September 9, 2026, he received 7,217 restricted stock units, each convertible into one common share, which will vest on September 9, 2027, subject to his continued service. On September 8, 2026, he sold 2,932 common shares in a nondiscretionary, sell-to-cover transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, at a weighted average price of $25.1287 per share.